GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Forward Rate of Return (Yacktman) %

CPMD (Cannapharmarx) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Cannapharmarx's forward rate of return for was 0.00%.

The historical rank and industry rank for Cannapharmarx's Forward Rate of Return (Yacktman) % or its related term are showing as below:

CPMD's Forward Rate of Return (Yacktman) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.22
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Cannapharmarx Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Cannapharmarx's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannapharmarx Forward Rate of Return (Yacktman) % Chart

Cannapharmarx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cannapharmarx Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cannapharmarx's Forward Rate of Return (Yacktman) %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannapharmarx's Forward Rate of Return (Yacktman) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's Forward Rate of Return (Yacktman) % falls into.


;
;

Cannapharmarx Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Cannapharmarx's Forward Rate of Return of Dec. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.0081+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannapharmarx  (OTCPK:CPMD) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Cannapharmarx Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannapharmarx Business Description

Industry
Traded in Other Exchanges
N/A
Address
3204-Rideau Place SW, Suite 302, Calgary, AB, CAN, T2S 1Z2
Cannapharmarx Inc specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. The group evolved to focus on producing medical cannabis and craft products. Its products Unique Genetics, Craft Products, and Medical Cannabis.
Executives
Anthony Michael Panek director 95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin director, officer: Chief Executive Officer C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels officer: Chief Financial Officer SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman director 302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman officer: Chief Operating Officer 1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson director 977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick 10 percent owner 7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson director PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia director, 10 percent owner 2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess director 2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood director P.O. BOX 4375, DILLON CO 80435
James E Smeeding director 4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife director 9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule director C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920